Abstract
The pharmacological treatment options for obesity are currently very limited but the prevalence of the disease is increasing rapidly. Obesity has many serious sequelae, the most common of which is type-2-diabetes. The benefits of weight loss on health are established but the major impediment to weight loss treatments is maintenance of weight lost over the long term. The reduced- or post-obese individual undergoes physiological changes that are geared towards energy storage and weight regain. One of the physiological changes is a reduced capacity to oxidise fatty acids pushing them through pathways of triacylglycerol synthesis. In this review, some of the past drug treatments aimed at increasing energy expenditure, such as dinitrophenol and ephedrine, are discussed. Current, or nearly current therapies such as sibutramine and rimonabant are also discussed in the context of increased energy expenditure. The main part of the review focuses on future prospects with discussion around a selection of targets with potential in energy expenditure that lie in pathways with AMP-kinase at their centre and ending at the mitochondrion.
Keywords: obesity, energy expenditure, type-2-diabetes
Current Drug Targets
Title: Treating Obesity: Pharmacology of Energy Expenditure
Volume: 5 Issue: 3
Author(s): John C. Clapham
Affiliation:
Keywords: obesity, energy expenditure, type-2-diabetes
Abstract: The pharmacological treatment options for obesity are currently very limited but the prevalence of the disease is increasing rapidly. Obesity has many serious sequelae, the most common of which is type-2-diabetes. The benefits of weight loss on health are established but the major impediment to weight loss treatments is maintenance of weight lost over the long term. The reduced- or post-obese individual undergoes physiological changes that are geared towards energy storage and weight regain. One of the physiological changes is a reduced capacity to oxidise fatty acids pushing them through pathways of triacylglycerol synthesis. In this review, some of the past drug treatments aimed at increasing energy expenditure, such as dinitrophenol and ephedrine, are discussed. Current, or nearly current therapies such as sibutramine and rimonabant are also discussed in the context of increased energy expenditure. The main part of the review focuses on future prospects with discussion around a selection of targets with potential in energy expenditure that lie in pathways with AMP-kinase at their centre and ending at the mitochondrion.
Export Options
About this article
Cite this article as:
Clapham C. John, Treating Obesity: Pharmacology of Energy Expenditure, Current Drug Targets 2004; 5 (3) . https://dx.doi.org/10.2174/1389450043490451
DOI https://dx.doi.org/10.2174/1389450043490451 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Having a Promising Efficacy on Type II Diabetes, It’s Definitely a Green Tea Time
Current Medicinal Chemistry Reappraising the Relationship Between Mitochondrial DNA Variant m.16189T>C and Type 2 Diabetes Mellitus in East Asian Populations
Current Molecular Medicine Angiotensin II Type I Receptor Blocker and Endothelial Function in Humans: Role of Nitric Oxide and Oxidative Stress
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Effect of Systemic Inflammation on the Function of Insulin and Glucose Metabolism in Rheumatoid Arthritis
Current Diabetes Reviews The Association of Lipodystrophy and Oxidative Stress Biomarkers in HIV-Infected Men
Current HIV Research Circulating and Vascular Bioactive Factors During Hypertension in Pregnancy
Current Bioactive Compounds Vitamin D and Vascular Disease
Current Vascular Pharmacology Immune System, Cell Senescence, Aging and Longevity - Inflamm-Aging Reappraised
Current Pharmaceutical Design Fetal Determinants of Type 2 Diabetes
Current Drug Targets Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency
Current Vascular Pharmacology Preconception Care for Diabetic Women: Background, Barriers, and Strategies for Effective Implementation
Current Diabetes Reviews Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism Strategies for Diabetes Prevention Before and After Pregnancy in Women with GDM
Current Diabetes Reviews The Leptin System: A Potential Target for Sepsis Induced Immune Suppression
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic Association Studies: An Information Content Perspective
Current Genomics The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms
Current Molecular Medicine Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery A Comparative Study Between the Leaf and Flowers of Some Asteraceae Plants With Respect to Their Antioxidant Activity Compounds
Current Nutrition & Food Science The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design